Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

FHS
July 17, 2024
9:58 am

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

Five Weeknight Dishes: Ali Slagle’s school for zucchini skeptics – The Cannabist

By Ali Slagle, The New York Times So often when I happen upon zucchini in a dish, it seems uncomfortable to be there, its texture

August 16, 2024

Changes in Siegfried’s senior management team – Biotech Investments

Siegfried AG / Key word(s): Personnel Changes in Siegfried’s senior management team 06.12.2024 / 06:30 CET/CEST Media ReleaseZofingen, December 6, 2024 Stefan Randl will join

December 7, 2024

Walmart WMT stock analysis – Sell WMT stock then buy Walmart as a value investment

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.